Genprex GPX-002 (AAV Pdx1 + MafA alpha-to-beta reprogramming)

Type 1 diabetes kills the pancreas's beta cells, but it spares their neighbors — the glucagon-making alpha cells. GPX-002, a gene therapy Genprex licensed from University of Pittsburgh researchers, exploits that. A single adeno-associated virus (AAV) vector delivers two transcription-factor genes, Pdx1 and MafA, into the pancreas, instructing some alpha cells to switch identity and become new insulin-producing, beta-like cells. Because the rebuilt cells arise inside the body, there is no transplant, no donor, and no encapsulation device — and, in principle, no need for lifelong immunosuppression.

The most relevant evidence for type 1 diabetes is preclinical. In foundational mouse work, including autoimmune NOD mice and chemically beta-cell-ablated mice, the two-gene therapy restored normal blood glucose and increased insulin-producing cell mass, with normoglycemia sustained for months after one dose. The researchers noted the converted cells may be different enough from native beta cells to partly escape the autoimmune attack that caused the disease — an appealing but still-unproven idea.

Where things stand: GPX-002 remains preclinical for T1D, with toxicology and non-human-primate studies underway ahead of any Investigational New Drug filing. A note of caution about reading the headlines: Genprex's most recent positive clinical-stage data were generated in type 2 diabetes models, and those results say nothing about type 1 efficacy. For T1D specifically, this is an early, mechanistically elegant program that has not yet reached the clinic.